0000950170-24-036006.txt : 20240325 0000950170-24-036006.hdr.sgml : 20240325 20240325172307 ACCESSION NUMBER: 0000950170-24-036006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240325 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240325 DATE AS OF CHANGE: 20240325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tivic Health Systems, Inc. CENTRAL INDEX KEY: 0001787740 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 814016391 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41052 FILM NUMBER: 24780207 BUSINESS ADDRESS: STREET 1: 25821 INDUSTRIAL BLVD., SUITE 100 CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (888)276-6888 MAIL ADDRESS: STREET 1: 25821 INDUSTRIAL BLVD., SUITE 100 CITY: HAYWARD STATE: CA ZIP: 94545 8-K 1 tivc-20240325.htm 8-K 8-K
0001787740false00017877402024-03-252024-03-25

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2024

 

 

Tivic Health Systems, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41052

81-4016391

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

25821 Industrial Blvd.,

Suite 100

 

Hayward, California

 

94545

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 888 276-6888

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

TIVC

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

 

The information provided below in “Item 7.01 - Regulation FD Disclosure” of this Current Report is incorporated by reference into this Item 2.02.

Item 7.01 Regulation FD Disclosure.

On March 25, 2024, Tivic Health Systems, Inc. (the "Company") issued a press release regarding the Company’s financial results for its fiscal year ended December 31, 2023. A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information set forth under Item 7.01 of this Current Report on Form 8-K (this "Current Report"), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Forward-Looking Statements

This Current Report, including Exhibit 99.1 attached hereto, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report, including Exhibit 99.1 attached hereto, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

Exhibits.

Exhibit
No.

Description

99.1

Press Release, dated March 25, 2024.

104

Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TIVIC HEALTH SYSTEMS, INC.

 

 

 

 

Date:

March 25, 2024

By:

/s/ Jennifer Ernst

 

 

 

Name: Jennifer Ernst
Title: Chief Executive Officer

 

 EX-99.1 2 tivc-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

img553027_0.jpg

 

Tivic Reports Fiscal Year 2023 Financial Results

SAN FRANCISCO – (Business Wire) – March 25, 2024 – Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023.

Tivic’s commercial platform is a handheld design that interfaces non-invasively with the trigeminal, sympathetic, and other facial and cranial nerve structures. This platform is the basis for Tivic’s existing product, currently marketed with FDA approval as ClearUP Sinus Pain Relief, for the treatment of sinus pain and congestion. In 2023, the company also began investment in a new platform for vagus nerve stimulation. Study enrollment for the pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) was completed on in February 2024. Results of the study have not yet been announced.

“2023 was a year for both streamlining our commercial business and defining new opportunities for value creation,” stated Jennifer Ernst, CEO of Tivic. "We have taken substantial steps towards improving the company’s financial health by implementing a new pricing structure on our commercial product, reducing costs of goods, improving marketing efficiency, and decreasing headcount to align with current revenue. We opened new channels directed to less price-sensitive healthcare segments. And, we strategically invested in clinical programs to create new paths for value creation for our shareholders, including a program in vagus nerve stimulation and one targeted to opiate-use reduction following sinus and facial surgeries."

 

As a result, the company was named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023 in the Medical Device category and Global Health & Pharma (GHP) named Tivic Health the Most Pioneering Bioelectronic Medicine Company.

2023 Financial Performance

•
Revenue (net of returns) for 2023 was $1.2M compared to $1.8M for the year ended December 31, 2022. The decrease of $664 thousand, or 36%, was due to a 52% decrease in ClearUP unit sales, offset by 46% higher average selling price per unit. Greater than 90% of sales were direct to consumer in 2023.
•
Cost of sales was $889 thousand in 2023 compared to $1.5M for the year ended December 31, 2022, a decrease of $652 thousand, or 42%. The decrease was due to the 52% decrease in overall unit sales, offset by $172 thousand of costs related to write-offs or reserves on old inventory and components primarily related to our ClearUP 1.0 units as our ClearUP 2.0 units began shipping in December of 2023. We do not expect to incur similar costs in 2024.
•
Gross profit for the year ended December 31, 2023 was $330 thousand compared to a gross profit of $299 thousand for the year ended December 31, 2022.

 

 

•
Research and development expenses were approximately $1.7M for each of the years ended December 31, 2023 and December 31, 2022. The emphasis of research and development activities in 2023 was primarily related to our work with The Feinstein Institutes.
•
Sales and marketing expenses decreased to $2.1M for the year ended December 31, 2023, compared to $2.8M for the year ended December 31, 2022. The decrease was primarily due to reduction of advertising and agency costs.
•
General and administrative expenses decreased to $4.8M in 2023, compared to $5.9M for the year ended December 31, 2022. The decrease is primarily due to a reduction in legal and professional fees and other corporate expenses as the company worked to reduce overhead costs.
•
As a result, our 2023 full year net loss was $8.2M, compared to $10.1M in 2022.

Regarding 2023 financing activities, on February 13, 2023, we sold shares of common stock to investors in a registered public offering, resulting in net proceeds of approximately $3.6M. From July 11, 2023 to August 9, 2023, we sold shares of common stock to investors in a series of registered public offerings, resulting in aggregate net proceeds to the company of approximately $4.3M.

 

On August 23, 2023, we implemented a 1-for-100 reverse stock split, and on September 15, 2023, we received confirmation from NASDAQ that we had regained compliance with the minimum bid price continued listing requirement.

As of December 31, 2023, the company had $3.4 million of cash and cash equivalents and we continued to maintain a no debt balance sheet.

 

The company’s MD&A and consolidated financial statements for the year-ended December 31, 2023 will be filed with the Securities and Exchange Commission on March 25, 2024 with the company’s Annual Report on Form 10-K. The company's previous public filings may be found on www.sec.gov and can also be located on Tivic’s website at: https://tivichealth.com/investor/#SEC.

 

Conference Call and Webcast Information

Management will host a webcast/conference call on Monday, March 25, 2024, at 1:30 PM PT / 4:30 PM ET to discuss the company’s year-end 2023 financial results and provide a business update, including comments on research directions undertaken in 2023.

The conference call will be available via telephone by dialing toll-free 888-506-0062 for local callers; or 973-528-0011 for international callers and using entry code 434944.

The conference call will also be available via Webcast link: https://www.webcaster4.com/Webcast/Page/2865/50026

 

An audio replay of the call will be available from the “Investor” page on the Tivic Health website at https://tivichealth.com/investor/.

About Tivic

 

 

Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic’s first commercial product, ClearUP, is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information, visit http://tivichealth.com@TivicHealth

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: market, economic and other conditions; supply chain constraints; macroeconomic factors, including inflation; the company's financial condition; the company’s ability to raise additional capital on favorable terms if and when necessary; changes in regulatory requirements; and unexpected costs, charges or expenses that reduce Tivic’s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic’s actual results to differ from those contained in the forward-looking statements, see Tivic’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, to be filed with the SEC on March 25, 2024, under the heading “Risk Factors,” as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

Investor Contact:
Hanover International, Inc.
ir@tivichealth.com


 

 

 

 

Tivic Health Systems, Inc.

Condensed Balance Sheets

(in thousands, except share and per share data)

 

 

December 31, 2023

 

 

December 31, 2022

 

ASSETS

 

 

 

 

 

 

Cash and cash equivalents

 

$

3,395

 

 

$

3,517

 

Other current assets

 

 

1,257

 

 

 

1,789

 

TOTAL CURRENT ASSETS

 

 

4,652

 

 

 

5,306

 

PROPERTY AND EQUIPMENT, NET

 

 

122

 

 

 

12

 

NONCURRENT ASSETS

 

 

383

 

 

 

557

 

TOTAL ASSETS

 

$

5,157

 

 

$

5,875

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

1,208

 

 

$

1,715

 

Other current liabilities

 

 

193

 

 

 

163

 

TOTAL CURRENT LIABILITIES

 

 

1,401

 

 

 

1,878

 

TOTAL LONG-TERM LIABILITIES

 

 

176

 

 

 

367

 

STOCKHOLDERS' EQUITY

 

 

 

 

 

 

Common stock

 

 

—

 

 

 

—

 

Additional paid in capital

 

 

41,466

 

 

 

33,272

 

Accumulated deficit

 

 

(37,886

)

 

 

(29,642

)

TOTAL STOCKHOLDERS' EQUITY

 

 

3,580

 

 

 

3,630

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

 

$

5,157

 

 

$

5,875

 

 

 

 

Tivic Health Systems, Inc.

Condensed Statements of Operations

(in thousands, except share and per share data)

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

REVENUES

 

$

1,176

 

 

$

1,840

 

COST OF SALES

 

 

889

 

 

 

1,541

 

GROSS PROFIT

 

 

287

 

 

 

299

 

OPERATING EXPENSES

 

 

 

 

 

 

Research and development

 

 

1,655

 

 

 

1,730

 

Sales and marketing

 

 

2,125

 

 

 

2,792

 

General and administrative

 

 

4,752

 

 

 

5,875

 

TOTAL OPERATING EXPENSES

 

 

8,532

 

 

 

10,397

 

NET OPERATING LOSS

 

 

(8,245

)

 

 

(10,098

)

NET LOSS

 

$

(8,244

)

 

$

(10,096

)

NET LOSS PER SHARE - BASIC AND DILUTED

 

$

(10.40

)

 

$

(104.32

)

WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED

 

 

793,043

 

 

 

96,778

 

 

 

 GRAPHIC 3 img553027_0.jpg GRAPHIC begin 644 img553027_0.jpg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end EX-101.SCH 4 tivc-20240325.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document And Entity Information
Mar. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 25, 2024
Entity Registrant Name Tivic Health Systems, Inc.
Entity Central Index Key 0001787740
Entity Emerging Growth Company true
Entity File Number 001-41052
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-4016391
Entity Address, Address Line One 25821 Industrial Blvd.,
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Hayward
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94545
City Area Code 888
Local Phone Number 276-6888
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol TIVC
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports tivc-20240325.htm tivc-20240325.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tivc-20240325.htm": { "nsprefix": "tivc", "nsuri": "http://www.tivichealthsystems.com/20240325", "dts": { "inline": { "local": [ "tivc-20240325.htm" ] }, "schema": { "local": [ "tivc-20240325.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_f9a75615-1edd-4e58-a000-dd469c1463e9", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tivc-20240325.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f9a75615-1edd-4e58-a000-dd469c1463e9", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tivc-20240325.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.tivichealthsystems.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-036006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-036006-xbrl.zip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�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end XML 16 tivc-20240325_htm.xml IDEA: XBRL DOCUMENT 0001787740 2024-03-25 2024-03-25 0001787740 false 8-K 2024-03-25 Tivic Health Systems, Inc. DE 001-41052 81-4016391 25821 Industrial Blvd., Suite 100 Hayward CA 94545 888 276-6888 false false false false Common Stock, par value $0.0001 per share TIVC NASDAQ true false